FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045016959> ?p ?o ?g. }

• W2045016959 endingPage "557" @default.
• W2045016959 startingPage "553" @default.
• W2045016959 abstract "1. Leukaemia inhibitory factor (LIF) is a 180 amino acid single-chain protein, named after its effect on haematopoietic cells. Leukaemia inhibitory factor belongs to a group of cytokines that includes ciliary neurotrophic factor, interleukin (IL)-6, IL-11, cardiotrophin-1 and oncostatin M. All group members use the gp130 signal transducing subunit for intracellular signalling, but show differences in biological effect. 2. Research over the past 6-8 years has shown LIF to have potent neuromuscular activity. In vitro and in vivo studies on axotomy and nerve crush models demonstrate a powerful effect of LIF in enhancing the survival of both motor and sensory neurons, while reducing denervation-induced muscle atrophy. In models of both axotomy induced neuronal death and in the wobbler mouse, LIF is active at doses as low as 1 microgram/kg delivered systemically. 3. In muscle, LIF will increase the rate of muscle regeneration in vivo when applied exogenously after injury and will stimulate intrinsic muscle repair following its targeted release to dystrophic muscle in the mdx mouse. Leukaemia inhibitory factor may also have a role as an adjunct to myoblast transfer therapy, with studies showing that the transplantation of genetically competent myoblasts into mdx mouse muscle is enhanced when cells are injected with LIF. 4. Distribution and pharmacokinetic studies have been conducted in primates with doses of 20 micrograms/kg recombinant human LIF given subcutaneously over 2 weeks tolerated without major side effects. 5. A pharmaceutical form of recombinant human LIF (AM424; AMRAD Operations, Richmond, Victoria, Australia) entered human clinical trials during 1997 and a phase I clinical trial in healthy volunteers has been completed. A phase I repeat dose study has also been completed in cancer patients undergoing chemotherapy. The primary indication for a phase II study is the treatment of chemotherapy induced peripheral neuropathy. Other potential indications include muscle wasting diseases, acute nerve trauma and motor neuron disease. 6. The role of LIF in modulating nerve loss should make it an ideal candidate for the treatment of a number of neurological conditions. The phase I study represents the first trial in a programme for the clinical development of AM424." @default.
• W2045016959 created "2016-06-24" @default.
• W2045016959 creator A5026678923 @default.
• W2045016959 date "2000-07-17" @default.
• W2045016959 modified "2023-10-17" @default.
• W2045016959 title "AM424: History Of A Novel Drug Candidate" @default.
• W2045016959 cites W1496712622 @default.
• W2045016959 cites W1511660468 @default.
• W2045016959 cites W1608821961 @default.
• W2045016959 cites W1679749381 @default.
• W2045016959 cites W1965040554 @default.
• W2045016959 cites W1968814677 @default.
• W2045016959 cites W1981708920 @default.
• W2045016959 cites W1986605550 @default.
• W2045016959 cites W1987045501 @default.
• W2045016959 cites W1990380467 @default.
• W2045016959 cites W1999534633 @default.
• W2045016959 cites W2000937423 @default.
• W2045016959 cites W2013881442 @default.
• W2045016959 cites W2029519036 @default.
• W2045016959 cites W2030541760 @default.
• W2045016959 cites W2032519256 @default.
• W2045016959 cites W2033962033 @default.
• W2045016959 cites W2039939841 @default.
• W2045016959 cites W2043222621 @default.
• W2045016959 cites W2048107450 @default.
• W2045016959 cites W2049177999 @default.
• W2045016959 cites W2054954302 @default.
• W2045016959 cites W2056077945 @default.
• W2045016959 cites W2059782202 @default.
• W2045016959 cites W2064375911 @default.
• W2045016959 cites W2088874236 @default.
• W2045016959 cites W2090338887 @default.
• W2045016959 cites W2094111001 @default.
• W2045016959 cites W2115437386 @default.
• W2045016959 cites W2166670696 @default.
• W2045016959 cites W4241612194 @default.
• W2045016959 cites W4249791753 @default.
• W2045016959 doi "https://doi.org/10.1046/j.1440-1681.2000.03289.x" @default.
• W2045016959 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10874517" @default.
• W2045016959 hasPublicationYear "2000" @default.
• W2045016959 type Work @default.
• W2045016959 sameAs 2045016959 @default.
• W2045016959 citedByCount "19" @default.
• W2045016959 countsByYear W20450169592012 @default.
• W2045016959 countsByYear W20450169592014 @default.
• W2045016959 crossrefType "journal-article" @default.
• W2045016959 hasAuthorship W2045016959A5026678923 @default.
• W2045016959 hasConcept C11988809 @default.
• W2045016959 hasConcept C126322002 @default.
• W2045016959 hasConcept C134018914 @default.
• W2045016959 hasConcept C150903083 @default.
• W2045016959 hasConcept C160539049 @default.
• W2045016959 hasConcept C170493617 @default.
• W2045016959 hasConcept C207001950 @default.
• W2045016959 hasConcept C207200792 @default.
• W2045016959 hasConcept C27284151 @default.
• W2045016959 hasConcept C2776263037 @default.
• W2045016959 hasConcept C2778690821 @default.
• W2045016959 hasConcept C2778943923 @default.
• W2045016959 hasConcept C2779683492 @default.
• W2045016959 hasConcept C2779959927 @default.
• W2045016959 hasConcept C3763915 @default.
• W2045016959 hasConcept C529278444 @default.
• W2045016959 hasConcept C68710172 @default.
• W2045016959 hasConcept C71924100 @default.
• W2045016959 hasConcept C86803240 @default.
• W2045016959 hasConcept C98274493 @default.
• W2045016959 hasConceptScore W2045016959C11988809 @default.
• W2045016959 hasConceptScore W2045016959C126322002 @default.
• W2045016959 hasConceptScore W2045016959C134018914 @default.
• W2045016959 hasConceptScore W2045016959C150903083 @default.
• W2045016959 hasConceptScore W2045016959C160539049 @default.
• W2045016959 hasConceptScore W2045016959C170493617 @default.
• W2045016959 hasConceptScore W2045016959C207001950 @default.
• W2045016959 hasConceptScore W2045016959C207200792 @default.
• W2045016959 hasConceptScore W2045016959C27284151 @default.
• W2045016959 hasConceptScore W2045016959C2776263037 @default.
• W2045016959 hasConceptScore W2045016959C2778690821 @default.
• W2045016959 hasConceptScore W2045016959C2778943923 @default.
• W2045016959 hasConceptScore W2045016959C2779683492 @default.
• W2045016959 hasConceptScore W2045016959C2779959927 @default.
• W2045016959 hasConceptScore W2045016959C3763915 @default.
• W2045016959 hasConceptScore W2045016959C529278444 @default.
• W2045016959 hasConceptScore W2045016959C68710172 @default.
• W2045016959 hasConceptScore W2045016959C71924100 @default.
• W2045016959 hasConceptScore W2045016959C86803240 @default.
• W2045016959 hasConceptScore W2045016959C98274493 @default.
• W2045016959 hasIssue "7" @default.
• W2045016959 hasLocation W20450169591 @default.
• W2045016959 hasLocation W20450169592 @default.
• W2045016959 hasOpenAccess W2045016959 @default.
• W2045016959 hasPrimaryLocation W20450169591 @default.
• W2045016959 hasRelatedWork W2002950232 @default.
• W2045016959 hasRelatedWork W2013167217 @default.
• W2045016959 hasRelatedWork W2029519036 @default.
• W2045016959 hasRelatedWork W2063711010 @default.
• W2045016959 hasRelatedWork W2081639867 @default.

• next